Nakajima Miki, Yokoi Tsuyoshi
Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.
Int J Clin Oncol. 2005 Feb;10(1):14-9. doi: 10.1007/s10147-004-0463-8.
Pharmacogenomics is the study of how genetic inheritance influences the responses to drugs. Genetic polymorphisms in drug-metabolizing enzymes result in altered pharmacokinetics in therapeutic drugs. In recent years, there has been great progress in our knowledge of the effects of cytochrome P450 (CYP) polymorphisms on the pharmacokinetics of therapeutic drugs. CYP enzymes catalyze the activation or detoxification of several anticancer drugs. Anticancer drugs generally have a narrow therapeutic margin. Therefore, the interindividual variability in their efficacy and toxicity is a major problem in clinical practice. In this review, genetic polymorphisms of CYP enzymes and their clinical relevance in cancer chemotherapy are discussed.
药物基因组学是研究遗传继承如何影响药物反应的学科。药物代谢酶中的基因多态性会导致治疗药物的药代动力学发生改变。近年来，我们对细胞色素P450（CYP）多态性对治疗药物药代动力学影响的认识有了很大进展。CYP酶催化几种抗癌药物的活化或解毒。抗癌药物通常治疗窗较窄。因此，它们在疗效和毒性方面的个体间差异是临床实践中的一个主要问题。在本综述中探讨了CYP酶的基因多态性及其在癌症化疗中的临床相关性。
